Cargando…

11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation

BACKGROUND: The European Society for Medical Oncology (ESMO) 2021 conference provided a high number of randomized phase III trial reports, many of which were claimed to be practice changing. Given the short time available for conference presentations, results and conclusions tend to have greatest pr...

Descripción completa

Detalles Bibliográficos
Autores principales: van Halteren, H.K., Tan, A., Pellegrino, B., Brasiuniene, B., Bennouna, J., Cunquero-Tomás, A.J., Strijbos, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783088/
https://www.ncbi.nlm.nih.gov/pubmed/35051788
http://dx.doi.org/10.1016/j.esmoop.2021.100376
_version_ 1784638448053780480
author van Halteren, H.K.
Tan, A.
Pellegrino, B.
Brasiuniene, B.
Bennouna, J.
Cunquero-Tomás, A.J.
Strijbos, M.
author_facet van Halteren, H.K.
Tan, A.
Pellegrino, B.
Brasiuniene, B.
Bennouna, J.
Cunquero-Tomás, A.J.
Strijbos, M.
author_sort van Halteren, H.K.
collection PubMed
description BACKGROUND: The European Society for Medical Oncology (ESMO) 2021 conference provided a high number of randomized phase III trial reports, many of which were claimed to be practice changing. Given the short time available for conference presentations, results and conclusions tend to have greatest priority with less time remaining for study background and study methodology. PURPOSE: On behalf of the ESMO Practicing Oncologists Working Group, 11 potentially practice-changing reports were selected and screened for three main questions: (i) Did the investigators provide sufficient details with regard to Patients and Methods to make the results comprehensible? (ii) Were there any reasons to consider bias? (iii) To which extent did the results presented translate to clinical benefit? RESULTS: In 2 out of 11 trials, the study design presented differed considerably from the study design described at ClinicalTrials.gov. Allocation concealment was not carried out in 6 out of 11 trials. In none of the trials reporting progression-free survival was informative censoring considered an issue. In none of the trials reporting overall survival was desirable crossover considered an issue. Defined trial outcome measures depicted at ClinicalTrials.gov, which could boost or weaken the ESMO-Magnitude of Clinical Benefit Scale score, were often lacking in the presentation. Study success was claimed in a heterogeneous manner, which was often not clearly linked to overall clinical benefit. CONCLUSION: ESMO conference presentations can inform the scientific community and catalyze further research but cannot replace the full papers in peer-reviewed journals, which are needed to estimate the thoroughness of the results, the overall impact on clinical benefit and the consequences for future treatment guidelines.
format Online
Article
Text
id pubmed-8783088
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-87830882022-01-28 11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation van Halteren, H.K. Tan, A. Pellegrino, B. Brasiuniene, B. Bennouna, J. Cunquero-Tomás, A.J. Strijbos, M. ESMO Open Review BACKGROUND: The European Society for Medical Oncology (ESMO) 2021 conference provided a high number of randomized phase III trial reports, many of which were claimed to be practice changing. Given the short time available for conference presentations, results and conclusions tend to have greatest priority with less time remaining for study background and study methodology. PURPOSE: On behalf of the ESMO Practicing Oncologists Working Group, 11 potentially practice-changing reports were selected and screened for three main questions: (i) Did the investigators provide sufficient details with regard to Patients and Methods to make the results comprehensible? (ii) Were there any reasons to consider bias? (iii) To which extent did the results presented translate to clinical benefit? RESULTS: In 2 out of 11 trials, the study design presented differed considerably from the study design described at ClinicalTrials.gov. Allocation concealment was not carried out in 6 out of 11 trials. In none of the trials reporting progression-free survival was informative censoring considered an issue. In none of the trials reporting overall survival was desirable crossover considered an issue. Defined trial outcome measures depicted at ClinicalTrials.gov, which could boost or weaken the ESMO-Magnitude of Clinical Benefit Scale score, were often lacking in the presentation. Study success was claimed in a heterogeneous manner, which was often not clearly linked to overall clinical benefit. CONCLUSION: ESMO conference presentations can inform the scientific community and catalyze further research but cannot replace the full papers in peer-reviewed journals, which are needed to estimate the thoroughness of the results, the overall impact on clinical benefit and the consequences for future treatment guidelines. Elsevier 2022-01-17 /pmc/articles/PMC8783088/ /pubmed/35051788 http://dx.doi.org/10.1016/j.esmoop.2021.100376 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
van Halteren, H.K.
Tan, A.
Pellegrino, B.
Brasiuniene, B.
Bennouna, J.
Cunquero-Tomás, A.J.
Strijbos, M.
11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation
title 11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation
title_full 11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation
title_fullStr 11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation
title_full_unstemmed 11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation
title_short 11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation
title_sort 11 esmo 2021 breakthroughs: practicing oncologist’s perceptions on data presentation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783088/
https://www.ncbi.nlm.nih.gov/pubmed/35051788
http://dx.doi.org/10.1016/j.esmoop.2021.100376
work_keys_str_mv AT vanhalterenhk 11esmo2021breakthroughspracticingoncologistsperceptionsondatapresentation
AT tana 11esmo2021breakthroughspracticingoncologistsperceptionsondatapresentation
AT pellegrinob 11esmo2021breakthroughspracticingoncologistsperceptionsondatapresentation
AT brasiunieneb 11esmo2021breakthroughspracticingoncologistsperceptionsondatapresentation
AT bennounaj 11esmo2021breakthroughspracticingoncologistsperceptionsondatapresentation
AT cunquerotomasaj 11esmo2021breakthroughspracticingoncologistsperceptionsondatapresentation
AT strijbosm 11esmo2021breakthroughspracticingoncologistsperceptionsondatapresentation
AT 11esmo2021breakthroughspracticingoncologistsperceptionsondatapresentation